EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share (FOCL)

Focal One sales grew, but deal timing pushed some placements into Q4.

FocalTherics (NASDAQ:FOCL) reported 26% growth in third-quarter 2026 revenue from its high-intensity focused ultrasound business, but lowered the top end of its full-year forecast after three anticipated system sales slipped into the fourth quarter. Revenue was $9.8 million, up from $7.8 million a

Insiders at H.B. Fuller, FocalTherics, and Cardinal Infrastructure Group are buying shares, signaling potential bottoms backed by analyst price targets, institutional ownership, and growth catalysts.

HIFU revenue surged 39% as system sales jumped 44%, signaling strong adoption momentum.

FocalTherics (NASDAQ:FOCL) reported second-quarter HIFU revenue of $13.2 million, up 39% from $9.5 million a year earlier, as the company continued to expand sales of its Focal One high-intensity focused ultrasound platform for focal therapy. Chief Executive Officer Ryan Rhodes characterized the pe

Edap TMS (NASDAQ:FOCL) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by Benzinga APIs. For